<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Shandong Fontacea Pharmaceutical Co. Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=34256></link><description><![CDATA[Shandong Fontacea Pharmaceutical Co. Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 03:43:13 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/12/12_3554238800_20191218094932_6311131823.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[산둥 폰타시아, 항IL17A 단일클론 항체 개발 및 상용화 위해 얀센과 라이선스 계약]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899059</link><description><![CDATA[지난, 산둥성, 중국--(Business Wire/뉴스와이어)--산둥 폰타시아 파마슈티컬(Shandong Fontacea Pharmaceutical Co. Ltd., 이하 폰타시아)이 얀센 바이오텍(Janssen Biotech, Inc.)과 독점 라이선스, 개발 및 상용화 계약을 체결했다고 17일 발표했다.  이 계약은 홍콩 특별행정구역(Hong Kong Special Administrative Region), 마카오 특별행정구역(Macao Special Administrative Region)을 포함한 중화인민공화국(People’s...]]></description><pubDate>Wed, 18 Dec 2019 14:26:42 +0900</pubDate></item><item><title><![CDATA[Shandong Fontacea Announces License Agreement with Janssen to Develop and Commercialize Anti-IL17A Monoclonal Antibody]]></title><link>https://www.newswire.co.kr/newsRead.php?no=899058</link><description><![CDATA[JINAN, Shandong,China--(Business Wire/Korea Newswire)--Shandong Fontacea Pharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license, development and commercialization agreement with Janssen Biotech, Inc., to develop and commercialize pharmaceutical products containing a human IgG1λ anti-human IL-17A neutralizing monoclonal antibody in People’s Republic of Chin...]]></description><pubDate>Wed, 18 Dec 2019 13:45:37 +0900</pubDate></item></channel></rss>